OT-S00X: A small molecule inhibitor
-
Designed to target metabolic stress adaptation in cancer cells and overcome drug resistance.
-
Proof-of-principle achieved with a prototype
-
Two chemical series have been identified, and one patent application has been filed to date
Current status: lead optimization
Created with BioRender.com
Created with BioRender.com
OT-A30X : An innovative multi-specific program
-
Promising targets identified to treat cancer and therapeutic resistance
-
Ongoing design for bi-specific, tri-specific and drug conjugate antibodies
Current status: binder discovery
OT-A201: A bispecific antibody (bsAb)
-
OT-A201 is designed from a new patented bispecific format
-
OT-A201 is a second-generation immune checkpoint inhibitor (ICI) which targets an ICI and its resistance mechanism
-
OT-A201 retains a competent Fc and its effector functions (ADCC, ADCP, CDC) unlike most ICIs. It utilizes both adaptative and innate immune mechanisms to destroy cancer cells
-
Protected by 4 patent families
Current status : Phase 1 (A20101) conducted in patients with selected relapsed/refractory hematologic malignancies and advanced / metastatic solid tumors (NCT05828459)
Pipeline
Onward Therapeutic’s multi-modality approaches are designed to overcome resistance and broaden patient access to innovative therapies
We aim to have three clinical programs by 2029, with the opportunity for licensing-out after achieving clinical Proof-of Concept (PoC) or reaching the most value creating inflection point.
OT-A201: A bispecific antibody (bsAb)
-
OT-A201 is designed from a new patented bispecific format
-
OT-A201 is a second-generation immune checkpoint inhibitor (ICI) which targets an ICI and its resistance mechanism
-
OT-A201 retains a competent Fc and its effector functions (ADCC, ADCP, CDC) unlike most ICIs. It utilizes both adaptative and innate immune mechanisms to destroy cancer cells
-
Protected by 4 patent families
Current status : Phase 1 (A20101) conducted in patients with selected relapsed/refractory hematologic malignancies and advanced/metastatic solid tumors (NCT05828459)
Created with BioRender.com
Created with BioRender.com
OT-C001 : Allogenic NK cells from pooled UCBs
-
Allogeneic NK cells derived from pooled umbilical cord blood (UCB), activated and expanded ex vivo using proprietary accessory cells and a patented process
-
NK cells can be used in various diseases such as hematologic malignancies (AML, ALL, MDS, CLL and NH-BCL), solid tumors (glioblastoma, NSCLC…), pediatric tumors (neuroblastoma…), post-transplant immune support, viral infection in immunocompromised, or immunosuppressed patients (hCMV, EBV, BK virus, adenovirus, …), or autoimmune and inflammatory diseases
-
Proof-of-concept ongoing in diffuse large B cell lymphoma (DLBCL)
-
Designed to enhance antibody-dependent cellular cytotoxicity (ADCC) overcoming antibody and NK cell resistance when used in combination for cancer treatment
-
Patented manufacturing process allowing full industrialization using the same batch of NK cells for many patients
Current status: Phase 1 study (C00101) in patients with relapsed/refractory DLBCL after CAR T cells failure. NCT07044050
OT-C001 : Allogenic NK cells from pooled UCBs
-
Allogeneic NK cells derived from pooled umbilical cord blood (UCB), activated and expanded ex vivo using proprietary accessory cells and a patented process
-
NK cells can be used in various diseases such as hematologic malignancies (AML, ALL, MDS, CLL and NH-BCL), solid tumors (glioblastoma, NSCLC…), pediatric tumors (neuroblastoma…), post-transplant immune support, viral infection in immunocompromised, or immunosuppressed patients (hCMV, EBV, BK virus, adenovirus, …), or autoimmune and inflammatory diseases
-
Proof-of-concept ongoing in diffuse large B cell lymphoma (DLBCL)
-
Designed to enhance antibody-dependent cellular cytotoxicity (ADCC) overcoming antibody and NK cell resistance when used in combination for cancer treatment
-
Patented manufacturing process allowing full industrialization using the same batch of NK cells for many patients
Current status : Phase 1 study (C00101) in patients with relapsed/refractory DLBCL after CAR T cells failure. NCT07044050
OT-S00X: A small molecule inhibitor
-
Designed to target metabolic stress adaptation in cancer cells and overcome drug resistance.
-
Proof-of-principle achieved with a prototype
-
Two chemical series have been identified, and one patent application has been filed to date
Current status: lead optimization
OT-A30X : An innovative multi-specific program
-
Promising targets identified to treat cancer and therapeutic resistance
-
Ongoing design for bi-specific, tri-specific and drug conjugate antibodies
Current status: binder discovery